Stifel expects Celcuity shares to move ‘meaningfully higher’ after data

After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant in adults with hormone receptor-positive, human epidermal growth factor receptor 2-negative, PIK3CA wild-type, locally advanced or metastatic breast cancer, Stifel said the firm expects shares to move “meaningfully higher” following the first Phase 3 disclosure. The inclusion of mechanism-sensitive PIK3CAm patients “should only enhance the competitiveness” of the Celcuity triplet against competitor doublet approaches, adds the analyst, who has a Buy rating and $30 price target on the shares.